It is a sympathomimetic amine that suppresses appetite through a completely different mechanism, primarily by stimulating norepinephrine release in the brain
Wegovy or semaglutide prescribed specifically for weight loss in a patient without a qualifying diagnosis: Technically falls into the weight loss exclusion under IRS rules, which means it may not be eligible for HSA or FSA reimbursement
Understanding that these are class effects rather than tirzepatide-specific problems helps users anticipate what to expect regardless of which GLP-1 compound they choose
Key findings (Rodriguez et al., 2023) include: HbA1c reductions of up to 2.1% in 36 weeks
Fewer hospitalizations means fewer emergency absences
Combining the low doses with Noom's GLP-1 Companion support app "helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the US," said the company's chief medical officer, Dr Jeffrey Egler
